Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

11/14/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, we discuss a new study that explores the effect of various interventions aimed at combating sedentary behavior on blood pressure and pulse wave velocity (PWV), a key marker of arterial stiffness.

In this installment of Talking...

11/14/2024

Pharmacy Learning Network

Talking Therapeutics

New Debate About Flozins for Diabetes

11/08/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, we discuss new data comparing empagliflozin and dapagliflozin in patients with diabetes that show no difference in cardiovascular outcomes, underscoring the need for further studies.

In this installment of Talking...

11/08/2024

Pharmacy Learning Network

Talking Therapeutics

Addressing Racial Disparity Head-On

06/16/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week, Dr Jennings discusses an example of an effective pharmacist-driven intervention focused on improving racial disparity in health care.

This week, Dr Jennings discusses...

06/16/2021

Pharmacy Learning Network

Talking Therapeutics

Navigating the Omicron Hype: The Latest on Boosters

12/09/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews recent data on the Omicron variant, highlighting what pharmacists should keep in mind when advising patients to receive booster shots.

Dr Jennings reviews recent data...

12/09/2021

Pharmacy Learning Network

Talking Therapeutics

Sparing Red Blood Cells During Cardiac Surgery

08/04/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's issue of Talking Therapeutics, Dr Jennings weighs the potential risks and benefits of high- vs low-dose tranexamic acid for cardiac surgery.

In this week's issue of Talking...

08/04/2022

Pharmacy Learning Network

Talking Therapeutics

Cost Effectiveness of SGLT2 Inhibitors in Question for Patients With HFpEF

05/19/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings explores findings from a study in which researchers evaluated the cost effectiveness of SGLT2 inhibitors for patients with heart failure with preserved ejection fraction (HFpEF).

Dr Jennings explores findings...

05/19/2023

Pharmacy Learning Network

Talking Therapeutics

A Striking Win for Statins

05/24/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings explores a new paper outlining the potential benefit of statins on key outcomes in patients with heart failure with preserved ejection fraction (HFpEF).

In this installment of Talking...

05/24/2024

Pharmacy Learning Network

Talking Therapeutics

Heart Failure Treatment Insight From ACC.2021

05/19/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's installment of Talking Therapeutics, Dr Jennings offers a breakdown on the latest heart failure therapy data, which was recently presented at the American College of Cardiology's annual meeting.

In this week's installment of...

05/19/2021

Pharmacy Learning Network

Talking Therapeutics

Full Steam Ahead for SGLT2 Inhibitors

03/02/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's Talking Therapeutics column, Dr Jennings reviews new data on SGLT2 inhibitors for patients with heart failure with preserved ejection fraction.

In this week's Talking...

03/02/2022

Pharmacy Learning Network

Talking Therapeutics

New Data Emerges for Managing Type 2 Diabetes

10/06/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings explores research comparing the efficacy of several SGLT2 inhibitors as second-line therapy options for patients with type 2 diabetes who have been treated with metformin.

Dr Jennings explores research...

10/06/2022

Pharmacy Learning Network